Endo Announces FDA Approval of a New Formulation of Opana ER Designed To Be Crush-Resistant

Endo Pharmaceuticals

today announced that the U.S. Food and Drug Administration has approved a new formulation of Opana ER designed to be crush-resistant. "FDA's approval of this new formulation of Opana ER is an important milestone for both the Long Acting Opioid category as well as Endo's branded pharmaceutical portfolio," said Dr. Ivan Gergel, M.D., executive vice president, R&D and chief scientific officer, Endo Pharmaceuticals. "Patient safety is our top concern and addressing appropriate use of opioids is a responsibility that we take very seriously.  We firmly believe this new formulation of Opana ER, coupled with our long-term commitment to awareness and education around appropriate use of opioids will benefit patients, physicians and payers."